Floatz

floatz is setting a new standard for scientific diligence in biotech investing. Life-science investments are only as strong as the science behind them. Yet foundational scientific claims can fail quietly, often long before clinical failure becomes visible. This is why biotech investors lose billions each year, with late-stage failures destroying up to $800M per program, most often due to flawed biology. floatz uses AI-driven scientific reasoning to evaluate biology at the level of claims, evidence, and uncertainty. Our system connects fragmented literature, surfaces hidden contradictions and weak signals, and makes unresolved assumptions explicit so scientific risk is visible at the point of decision. We’ve flagged major failures ahead of time, including a $240M collapse, and partner with leading investors and institutions such as the ETH AI Center and Google for Startups. Scientific diligence, made decision-grade.